Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - Antidepressants: life cycle management to the rescue?

This article was originally published in Scrip

Executive Summary

Life cycle management approaches include the development of new formulations of drugs (for example, advanced delivery systems, metabolites or isomers) in order to improve the clinical performance and extend the patent life of well established drugs. In today's cost-containment environment, however, payers and physicians are challenging this strategy by asking tougher questions, such as ‘is the new drug superior to its predecessor?" and ‘if there is a benefit, is it marginal, or is it large enough to justify a significantly higher price, when compared with all prescription antidepressants?'

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC008159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel